M Bourdon1,2, M Blanchin3, P Tessier3, M Campone4, G Quéreux5, F Dravet4, V Sébille3, A Bonnaud-Antignac3,4. 1. EA 4275-SPHERE methodS for Patients-centered outcomes and HEalth REsearch, Université de Nantes, UFR des Sciences Pharmaceutiques, 1 rue Gaston Veil, BP 53508, 44035, Nantes Cedex 1, France. marianne.bourdon@univ-nantes.fr. 2. Institut de Cancérologie de l'Ouest, Site René Gauducheau, Boulevard Jacques Monod, 44805, Saint Herblain Cedex, France. marianne.bourdon@univ-nantes.fr. 3. EA 4275-SPHERE methodS for Patients-centered outcomes and HEalth REsearch, Université de Nantes, UFR des Sciences Pharmaceutiques, 1 rue Gaston Veil, BP 53508, 44035, Nantes Cedex 1, France. 4. Institut de Cancérologie de l'Ouest, Site René Gauducheau, Boulevard Jacques Monod, 44805, Saint Herblain Cedex, France. 5. Unité de Cancéro-dermatologie, Centre Hospitalier Universitaire de Nantes, 1 place Alexis-Ricordeau, 44093, Nantes Cedex 1, France.
Abstract
PURPOSE: Longitudinal studies addressing change in health-related quality of life (HRQoL) following a diagnosis of cancer have mainly focused on a single cancer type, and little is known about the differences in HRQoL over time according to the type of tumor. The current study aims to compare the change in HRQoL over 2 years following breast cancer or melanoma diagnosis and socio-demographic variables associated with HRQoL over time. METHODS: Patients recently diagnosed with breast cancer (n = 215) or melanoma (n = 78) completed surveys within 1 month of diagnosis and 6, 12, and 24 months later. Multilevel modeling analyses were used to compare the evolution over time of HRQoL dimensions, as measured by the EORTC QLQ-C30, in both cancers. Longitudinal effect of socio-demographic variables on HRQoL was also assessed. RESULTS: Consistent with the literature, both cancer patients experienced decreased HRQoL scores following the diagnosis before improving over time. However, our analyses revealed that this rebound effect may occur at diverse times over the course of the illness according to the type of cancer. In addition, HRQoL over time was positively associated with age and negatively related to living with a partner regardless of the type of cancer. CONCLUSIONS: The results of the present study suggest that support in hospital units should be specific and depend on the cancer type.
PURPOSE: Longitudinal studies addressing change in health-related quality of life (HRQoL) following a diagnosis of cancer have mainly focused on a single cancer type, and little is known about the differences in HRQoL over time according to the type of tumor. The current study aims to compare the change in HRQoL over 2 years following breast cancer or melanoma diagnosis and socio-demographic variables associated with HRQoL over time. METHODS:Patients recently diagnosed with breast cancer (n = 215) or melanoma (n = 78) completed surveys within 1 month of diagnosis and 6, 12, and 24 months later. Multilevel modeling analyses were used to compare the evolution over time of HRQoL dimensions, as measured by the EORTC QLQ-C30, in both cancers. Longitudinal effect of socio-demographic variables on HRQoL was also assessed. RESULTS: Consistent with the literature, both cancerpatients experienced decreased HRQoL scores following the diagnosis before improving over time. However, our analyses revealed that this rebound effect may occur at diverse times over the course of the illness according to the type of cancer. In addition, HRQoL over time was positively associated with age and negatively related to living with a partner regardless of the type of cancer. CONCLUSIONS: The results of the present study suggest that support in hospital units should be specific and depend on the cancer type.
Entities:
Keywords:
Breast cancer; Health-related quality of life; Longitudinal study; Melanoma; Oncology
Authors: A-G Le Corroller-Soriano; A-D Bouhnik; M Preau; L Malavolti; C Julian-Reynier; P Auquier; J-P Moatti Journal: Eur J Cancer Care (Engl) Date: 2011-01 Impact factor: 2.520
Authors: Delphine Klein; Mariette Mercier; Edwige Abeilard; Marc Puyraveau; Arlette Danzon; Véronique Dalstein; Astrid Pozet; Anne-Valérie Guizard; Michel Henry-Amar; Michel Velten Journal: Breast Cancer Res Treat Date: 2011-02-22 Impact factor: 4.872
Authors: Alice B Kornblith; Mark Powell; Meredith M Regan; Samantha Bennett; Carolyn Krasner; Beverly Moy; Jerry Younger; Annekathyrn Goodman; Ross Berkowitz; Eric Winer Journal: Psychooncology Date: 2007-10 Impact factor: 3.894
Authors: Kristin Härtl; Jutta Engel; Peter Herschbach; Hans Reinecker; Harald Sommer; Klaus Friese Journal: Psychooncology Date: 2010-02 Impact factor: 3.894
Authors: N K Aaronson; S Ahmedzai; B Bergman; M Bullinger; A Cull; N J Duez; A Filiberti; H Flechtner; S B Fleishman; J C de Haes Journal: J Natl Cancer Inst Date: 1993-03-03 Impact factor: 13.506
Authors: Shoshana M Rosenberg; Rulla M Tamimi; Shari Gelber; Kathryn J Ruddy; Sandra Kereakoglow; Virginia F Borges; Steven E Come; Lidia Schapira; Eric P Winer; Ann H Partridge Journal: Psychooncology Date: 2012-11-07 Impact factor: 3.894
Authors: Tenbroeck G Smith; Alyssa N Troeschel; Kathleen M Castro; Neeraj K Arora; Kevin Stein; Joseph Lipscomb; Otis W Brawley; Ryan M McCabe; Steven B Clauser; Elizabeth Ward Journal: J Clin Oncol Date: 2019-05-17 Impact factor: 44.544
Authors: Jessica Ranieri; Dina Di Giacomo; Federica Guerra; Eleonora Cilli; Alessandra Martelli; Valeria Ciciarelli; Alessandra Ventura; Maria Concetta Fargnoli Journal: Int J Environ Res Public Health Date: 2022-07-28 Impact factor: 4.614
Authors: Patricia Markham Risica; Natalie H Matthews; Laura Dionne; Jennifer Mello; Laura K Ferris; Melissa Saul; Alan C Geller; Francis Solano; John M Kirkwood; Martin A Weinstock Journal: Prev Med Rep Date: 2018-04-17